Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1.

Christina R Bourne1, M G Finn, Adam Zlotnick

  • 1Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, 975 E. 10th Street, Oklahoma City, Oklahoma 73104, USA.

Journal of Virology
|September 1, 2006
PubMed
Summary

Hepatitis B virus (HBV) capsid assembly is a novel therapeutic target. The drug HAP1 activates and misdirects HBV capsid assembly by inducing global structural changes, offering a new antiviral strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Negative cooperativity drives activity of capsid-directed antivirals against hepatitis B virus.

Science advances·2026
Same author

Modeling Reveals How Direct-Acting Antivirals Redirect HBV Capsid Assembly Pathways to Noninfectious Products.

bioRxiv : the preprint server for biology·2026
Same author

Liquid-Phase CO<b><sub>2</sub></b> Capture by a Nonaqueous Cooperative Absorption Mechanism.

Journal of the American Chemical Society·2026
Same author

Characterization Standard for <i>In-situ</i> Cryo-electron Tomography.

bioRxiv : the preprint server for biology·2026
Same author

Orthogonal Chemistry Enables Precision Nanoparticle Cofunctionalization for Tuning Immune Stimulation and Antigen Presentation.

Biomacromolecules·2026
Same author

Assembly-active and -inactive forms of HBV capsid protein provide distinctly different binding sites for capsid assembly modulators.

bioRxiv : the preprint server for biology·2026

Area of Science:

  • Biochemistry
  • Structural Biology
  • Virology

Background:

  • Hepatitis B virus (HBV) causes significant liver disease and cancer, with over 400 million chronically infected individuals.
  • Current antiviral therapies often target host-similar enzymes, limiting specificity.
  • HBV capsid assembly presents a unique therapeutic target due to the absence of human homologs.

Purpose of the Study:

  • To elucidate the structural basis of HAP1's activity on HBV capsid assembly.
  • To provide a molecular understanding for developing capsid-targeting antiviral strategies.

Main Methods:

  • Determined crystal structures of icosahedral HBV capsids with and without the HAP1 compound.
  • Analyzed structural changes induced by HAP1 binding.

Related Experiment Videos

Main Results:

  • HAP1 binding induces global structural rearrangements in HBV capsids by rigid body movements of subunits.
  • Observed changes include protruding fivefold vertices, opening threefold vertices, and flattening quasi-sixfold vertices.
  • Identified a HAP1-binding site that likely explains assembly activation and misdirection by disrupting inter-subunit interactions.

Conclusions:

  • HAP1 acts as an HBV capsid assembly activator and misdirector through specific structural alterations.
  • These findings reveal the plasticity of HBV capsids and demonstrate a viable molecular basis for antiviral drug development targeting capsid assembly.